STAT3 Inhibition as a Therapeutic Strategy for Chordoma

Abstract

Objective Signal transducer and activator of transcription (STAT) proteins regulate key cellular fate decisions including proliferation and apoptosis. STAT3 overexpression induces tumor growth in multiple neoplasms. STAT3 is constitutively activated in chordoma, a tumor with a high recurrence rate despite maximal surgical and radiation treatment. We hypothesized that a novel small molecule inhibitor of STAT3 (FLLL32) would induce significant cytotoxicity in sacral and clival chordoma cells.

Methods Sacral (UCh1) and clival (UM-CHOR-1) chordoma cell lines were grown in culture (the latter derived from primary tumor explants). FLLL32 dosing parameters were optimized using cell viability assays. Antitumor potential of FLLL32 was assessed using clonal proliferation assays. Potential mechanisms underlying observed cytotoxicity were examined using immunofluorescence assays.

Results FLLL32 induced significant cytotoxicity in UCh1 and UM-CHOR-1 chordoma cells, essentially eliminating all viable cells, correlating with observed downregulation in activated, phosphorylated STAT3 upon administration of FLLL32. Mechanisms underlying the observed cytotoxicity included increased apoptosis and reduced cellular proliferation through inhibition of mitosis.

Conclusion As a monotherapy, FLLL32 induces potent tumor kill in vitro in chordoma cell lines derived from skull base and sacrum. This effect is mediated through inhibition of STAT3 phosphorylation, increased susceptibility to apoptosis, and suppression of cell proliferation.

Keywords

chordoma - FLLL32 - sacrum - skull base - STAT3

• References

• 1 Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Ferreira MJ. Chordoma: current concepts, management, and future directions. Lancet Oncol 2012; 13 (2) e69-e76
• 2 McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001; 12 (1) 1-11
• 3 Williams BJ, Raper DM, Godbout E , et al. Diagnosis and treatment of chordoma. J Natl Compr Canc Netw 2013; 11 (6) 726-731
• 4 Stacchiotti S, Casali PG. Systemic therapy options for unresectable and metastatic chordomas. Curr Oncol Rep 2011; 13 (4) 323-330
• 5 Di Maio S, Temkin N, Ramanathan D, Sekhar LN. Current comprehensive management of cranial base chordomas: 10-year meta-analysis of observational studies. J Neurosurg 2011; 115 (6) 1094-1105
• 6 Forsyth PA, Cascino TL, Shaw EG , et al. Intracranial chordomas: a clinicopathological and prognostic study of 51 cases. J Neurosurg 1993; 78 (5) 741-747
• 7 Catton C, O'Sullivan B, Bell R , et al. Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol 1996; 41 (1) 67-72
• 8 Cummings BJ, Hodson DI, Bush RS. Chordoma: the results of megavoltage radiation therapy. Int J Radiat Oncol Biol Phys 1983; 9 (5) 633-642
• 9 Martin JJ, Niranjan A, Kondziolka D, Flickinger JC, Lozanne KA, Lunsford LD. Radiosurgery for chordomas and chondrosarcomas of the skull base. J Neurosurg 2007; 107 (4) 758-764
• 10 Goitein M, Cox JD. Should randomized clinical trials be required for proton radiotherapy?. J Clin Oncol 2008; 26 (2) 175-176
• 11 Austin-Seymour M, Munzenrider J, Goitein M , et al. Fractionated proton radiation therapy of chordoma and low-grade chondrosarcoma of the base of the skull. J Neurosurg 1989; 70 (1) 13-17
• 12 Amichetti M, Cianchetti M, Amelio D, Enrici RM, Minniti G. Proton therapy in chordoma of the base of the skull: a systematic review. Neurosurg Rev 2009; 32 (4) 403-416
• 13 Koutourousiou M, Snyderman CH, Fernandez-Miranda J, Gardner PA. Skull base chordomas. Otolaryngol Clin North Am 2011; 44 (5) 1155-1171
• 14 Jian BJ, Bloch OG, Yang I , et al. Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma. J Neurooncol 2010; 98 (1) 101-108
• 15 Smoll NR, Gautschi OP, Radovanovic I, Schaller K, Weber DC. Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population. Cancer 2013; 119 (11) 2029-2037
• 16 Yang C, Hornicek FJ, Wood KB , et al. Characterization and analysis of human chordoma cell lines. Spine 2010; 35 (13) 1257-1264
• 17 Chugh R, Dunn R, Zalupski MM , et al. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol 2005; 23 (15) 3597-3604
• 18 Hof H, Welzel T, Debus J. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie 2006; 29 (12) 572-574
• 19 Singhal N, Kotasek D, Parnis FX. Response to erlotinib in a patient with treatment refractory chordoma. Anticancer Drugs 2009; 20 (10) 953-955
• 20 Le LP, Nielsen GP, Rosenberg AE , et al. Recurrent chromosomal copy number alterations in sporadic chordomas. PLoS ONE 2011; 6 (5) e18846
• 21 Choy E, MacConaill LE, Cote GM , et al. Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1. PLoS ONE 2014; 9 (7) e101283
• 22 Yang C, Hornicek FJ, Wood KB , et al. Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma. Spine 2010; 35 (18) 1668-1675
• 23 Yang C, Schwab JH, Schoenfeld AJ , et al. A novel target for treatment of chordoma: signal transducers and activators of transcription 3. Mol Cancer Ther 2009; 8 (9) 2597-2605
• 24 Lin L, Deangelis S, Foust E , et al. A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Mol Cancer 2010; 9: 217
• 25 Vega-Avila E, Pugsley MK. An overview of colorimetric assay methods used to assess survival or proliferation of mammalian cells. Proc West Pharmacol Soc 2011; 54: 10-14
• 26 Tamborini E, Miselli F, Negri T , et al. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res 2006; 12 (23) 6920-6928
• 27 Stacchiotti S, Longhi A, Ferraresi V , et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol 2012; 30 (9) 914-920
• 28 Casali PG, Messina A, Stacchiotti S , et al. Imatinib mesylate in chordoma. Cancer 2004; 101 (9) 2086-2097
• 29 Börgel J, Olschewski H, Reuter T, Miterski B, Epplen JT. Does the tuberous sclerosis complex include clivus chordoma? A case report. Eur J Pediatr 2001; 160 (2) 138
• 30 Kimmell KT, Dayoub H, Stolzenberg ED, Sincoff EH. Chordoma in the lateral medullary cistern in a patient with tuberous sclerosis: a case report and review of the literature. Surg Neurol Int 2010; 1: 13
• 31 Presneau N, Shalaby A, Idowu B , et al. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer 2009; 100 (9) 1406-1414
• 32 Hsu W, Mohyeldin A, Shah SR , et al. Generation of chordoma cell line JHC7 and the identification of brachyury as a novel molecular target. J Neurosurg 2011; 115 (4) 760-769
• 33 Vujovic S, Henderson S, Presneau N , et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 2006; 209 (2) 157-165
• 34 Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005; 16 (6) 601-607
• 35 Darnell Jr JE. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002; 2 (10) 740-749
• 36 Lin L, Hutzen B, Zuo M , et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 2010; 70 (6) 2445-2454
• 37 Grandis JR, Drenning SD, Zeng Q , et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 2000; 97 (8) 4227-4232
• 38 Yu H, Jove R. The STATs of cancer—new molecular targets come of age. Nat Rev Cancer 2004; 4 (2) 97-105
• 39 Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000; 19 (21) 2489-2495
• 40 Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19 (21) 2474-2488
• 41 Decker T, Kovarik P. Serine phosphorylation of STATs. Oncogene 2000; 19 (21) 2628-2637
• 42 Qin HR, Kim HJ, Kim JY , et al. Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation. Cancer Res 2008; 68 (19) 7736-7741
• 43 Huang G, Yan H, Ye S, Tong C, Ying QL. STAT3 phosphorylation at tyrosine 705 and serine 727 differentially regulates mouse ESC fates. Stem Cells 2014; 32 (5) 1149-1160
• 44 Bill MA, Fuchs JR, Li C , et al. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer 2010; 9: 165
• 45 Naka T, Narazaki M, Hirata M , et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997; 387 (6636) 924-929
• 46 Takemoto S, Mulloy JC, Cereseto A , et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci U S A 1997; 94 (25) 13897-13902
• 47 Niu G, Wright KL, Huang M , et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21 (13) 2000-2008
• 48 Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7 (1) 41-51
• 49 Duan Z, Bradner JE, Greenberg E , et al. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Clin Cancer Res 2006; 12 (22) 6844-6852